A Phase 3, Randomized, 24-week,Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Project: Research

Project Details

StatusActive
Effective start/end date10/03/23 → 10/03/25

Keywords

  • clinical trial
  • Atopic Dermatitis
  • Rocatinlimab
  • skin disease